TY - JOUR
T1 - Molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts
AU - Rhodes, Deborah J.
AU - Hruska, Carrie B.
AU - Conners, Amy Lynn
AU - Tortorelli, Cindy L.
AU - Maxwell, Robert W.
AU - Jones, Katie N.
AU - Toledano, Alicia Y.
AU - O'Connor, Michael K.
N1 - Publisher Copyright:
© American Roentgon Ray Society.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - OBJECTIVE. The purpose of this study was to assess the diagnostic performance of supplemental screening molecular breast imaging (MBI) in women with mammographically dense breasts after system modifications to permit radiation dose reduction. SUBJECTS AND METHODS. A total of 1651 asymptomatic women with mammographically dense breasts on prior mammography underwent screening mammography and adjunct MM performed with 300-MBq 99mTc-sestamibi and a direct-conversion (cadmium zinc telluride) gamma camera, both interpreted independently, The cancer detection rate, sensitivity, specificity, and positive predictive value of biopsies performed (PPV3) were determined. RESULTS. In 1585 participants with a complete reference standard, 21 were diagnosed with cancer: two detected by mammography only, 14 by MBI only, three by both modalities, and two by neither. Of 14 participants with cancers detected only by MBI, 11 had invasive disease (median size, 0.9 cm; range, 0.5-4.1 cm). Nine of 11 (82%) were node negative, and two had bilateral cancers. With the addition of MBI to mammography, the overall cancer detection rate (per 1000 screened) increased from 3.2 to 12.0 (p < 0.001) (supplemental yield 8.8). The invasive cancer detection rate increased from 1.9 to 8.8 (p < 0.001) (supplemental yield 6.9), a relative increase of 363%, while the change in DCIS detection was not statistically significant (from 1.3 to 3.2, p =0.250). For mammography alone, sensitivity was 24%; specificity, 89%; and PPV3, 25%. For the combination, sensitivity was 91% (p < 0.001); specificity, 83% (p < 0.001); and PPV3, 28% (p < = 0.70). The recall rate increased from 11.0% with mammography alone to 17.6% (p < 0.001) for the combination; the biopsy rate increased from 1.3% for mammography alone to 4.2% (p < 0.001). CONCLUSION. When added lo screening mammography. MBI performed using a radiopharmaceutical activity acceptable for screening (effective dose 2.4 mSv) yielded a supple-menial cancer detection rate of 8.8 per 1000 women with mammographically dense breasts.
AB - OBJECTIVE. The purpose of this study was to assess the diagnostic performance of supplemental screening molecular breast imaging (MBI) in women with mammographically dense breasts after system modifications to permit radiation dose reduction. SUBJECTS AND METHODS. A total of 1651 asymptomatic women with mammographically dense breasts on prior mammography underwent screening mammography and adjunct MM performed with 300-MBq 99mTc-sestamibi and a direct-conversion (cadmium zinc telluride) gamma camera, both interpreted independently, The cancer detection rate, sensitivity, specificity, and positive predictive value of biopsies performed (PPV3) were determined. RESULTS. In 1585 participants with a complete reference standard, 21 were diagnosed with cancer: two detected by mammography only, 14 by MBI only, three by both modalities, and two by neither. Of 14 participants with cancers detected only by MBI, 11 had invasive disease (median size, 0.9 cm; range, 0.5-4.1 cm). Nine of 11 (82%) were node negative, and two had bilateral cancers. With the addition of MBI to mammography, the overall cancer detection rate (per 1000 screened) increased from 3.2 to 12.0 (p < 0.001) (supplemental yield 8.8). The invasive cancer detection rate increased from 1.9 to 8.8 (p < 0.001) (supplemental yield 6.9), a relative increase of 363%, while the change in DCIS detection was not statistically significant (from 1.3 to 3.2, p =0.250). For mammography alone, sensitivity was 24%; specificity, 89%; and PPV3, 25%. For the combination, sensitivity was 91% (p < 0.001); specificity, 83% (p < 0.001); and PPV3, 28% (p < = 0.70). The recall rate increased from 11.0% with mammography alone to 17.6% (p < 0.001) for the combination; the biopsy rate increased from 1.3% for mammography alone to 4.2% (p < 0.001). CONCLUSION. When added lo screening mammography. MBI performed using a radiopharmaceutical activity acceptable for screening (effective dose 2.4 mSv) yielded a supple-menial cancer detection rate of 8.8 per 1000 women with mammographically dense breasts.
KW - Breast cancer
KW - Mammographic density
KW - Molecular breast imaging
KW - Supplemental screening
KW - Tc-sestamibi
UR - http://www.scopus.com/inward/record.url?scp=84928552150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928552150&partnerID=8YFLogxK
U2 - 10.2214/AJR.14.13357
DO - 10.2214/AJR.14.13357
M3 - Article
C2 - 25615744
AN - SCOPUS:84928552150
SN - 0361-803X
VL - 204
SP - 241
EP - 251
JO - American Journal of Roentgenology
JF - American Journal of Roentgenology
IS - 2
ER -